Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Target ID: TTDS00038

Target Information
NameNoradrenergic re-uptake    
Type of targetSuccessful target    
SynonymsNorepinephrine reuptake    
DiseaseDepression    [1][2]
Obesity    [3][4]
Post-anaesthetic shivering    [5]
St John's Wort    [6]
Drug(s)AmfepramoneApprovedObesity[7]
AmitriptylineApprovedDepression and chronic pain[8][9]
AmoxapineApprovedDepression[10]
AtomoxetineApprovedAttention deficit hyperactivity disorder[11][12]
BupropionApprovedDepression[13]
CocaineApprovedAnesthetic[14]
DesipramineApprovedDepression[15]
Desvenalfaxine succinateApprovedFibromyalgia[16]
DiethylpropionApprovedMigraine and Obisity[17]
DuloxetineApprovedDepression[18][19]
ImipramineApprovedDepression[20][21]
MaprotilineApprovedDepression[22]
MazindolApprovedObesity[4]
MilnacipranApprovedDepression[23]
NortriptylineApprovedDepression[24]
PhenmetrazineApprovedObesity[25]
PhentermineApprovedObesity[3]
ProtriptylineApprovedDepression[26]
ReboxetineApprovedDepression[1]
SibutramineApprovedObesity[27][4]
TrazodoneApprovedDepression[13][28]
TrimipramineApprovedDepression[29]
UltracetApprovedPain[15]
VenlafaxineApprovedDepression[13]
Trazodone CRPhase IV completedFibromyalgia, Major Depressive Disorder, Severe Mood Disorders[13]
ReboxetinePhase IVCerebral Stroke[30][31]
DesvenlafaxinePhase IIIMajor Depressive Disorder, Menopausal Staging and Vasomotor Symptoms (for Females), Severe Mood Disorders[32]
Desvenlafaxine SRPhase IIIDepressive Disorder, Painful diabetic neuropathy[30]
DOV 21947Phase IISevere Mood Disorders[32]
DOV-21947Phase IISevere Mood Disorders[32]
DOV-216303Discontinued in Phase IISevere Mood Disorders[32]
GSK372475Discontinued in Phase IIADHD; Severe Mood Disorders[32]
NS 2359Discontinued in 2009 in phase II Attention-deficit/hyperactivity disorder, depression and cocaine addiction[33]
R-sibutramine metaboliteDiscontinued in Phase IIDepression, Attention Deficit/Hyperactivity Disorder (ADHD)[32]
Related US Patent6,465,458
6,642,235
Target ValidationClick to Find Target Validation Information.    
InhibitorAmfepramone[7]
Amitriptyline[8][9]
Amoxapine[10]
Atomoxetine[11][12]
Bupropion[13]
Cocaine[14]
DOV 21947[32]
DOV-216303[32]
DOV-21947[32]
Desipramine[15]
Desvenalfaxine succinate[16]
Desvenlafaxine[32]
Desvenlafaxine SR[30]
Diethylpropion[17]
Duloxetine[18][19]
GSK372475[32]
Hypericum[6]
Imipramine[20][21]
Maprotiline[22]
Mazindol[4]
Milnacipran[23]
NS 2359[33]
Nortriptyline[24]
Phenmetrazine[25]
Phentermine[3]
Protriptyline[26]
R-sibutramine metabolite[32]
Reboxetine[30][31]
Reboxetine[1]
Sibutramine[27][4]
Trazodone[13][28]
Trazodone CR[13]
Trimipramine[29]
Ultracet[15]
Venlafaxine[13]
MultitargetAmfepramone[7]
Amitriptyline[8][9]
Bupropion[13]
Cocaine[14]
DOV 21947[32]
DOV-216303[32]
DOV-21947[32]
Desvenlafaxine SR[30]
Diethylpropion[17]
Duloxetine[18][19]
GSK372475[32]
NS 2359[33]
Phenmetrazine[25]
R-sibutramine metabolite[32]
Sibutramine[27][4]
Trazodone[13][28]
Trazodone CR[13]
Ultracet[15]
Venlafaxine[13]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. To Reference
Ref 2Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem. 2000 Mar;74(3):1257-62. To Reference
Ref 3Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. To Reference
Ref 4Drug treatment of obesity. Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Apr;13(1):131-48. To Reference
Ref 5Tramadol for postoperative shivering: a double-blind comparison with pethidine. Anaesth Intensive Care. 2001 Apr;29(2):149-54. To Reference
Ref 6The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8. To Reference
Ref 7Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. To Reference
Ref 8Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. To Reference
Ref 9A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90. To Reference
Ref 10Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. To Reference
Ref 11Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. Epub 2008 Jun 22. To Reference
Ref 12New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302. To Reference
Ref 13Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. To Reference
Ref 14Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. Epub 2009 Apr 17. To Reference
Ref 15Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11. [Epub ahead of print] To Reference
Ref 16Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. To Reference
Ref 17Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7. To Reference
Ref 18Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference
Ref 19Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31. Epub 2009 Apr 8. To Reference
Ref 20Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8. Epub 2008 Nov 30. To Reference
Ref 21Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83. To Reference
Ref 22Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28. To Reference
Ref 23Milnacipran: Beyond a Role of Antidepressant. Clin Neuropharmacol. 2009 Jun 10. [Epub ahead of print] To Reference
Ref 24Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009 Aug;9(4):225-33. Epub 2009 Apr 14. To Reference
Ref 25Eur J Pharmacol. 2002 Jun 28;447(1):51-7.Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. To Reference
Ref 26Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55. To Reference
Ref 27Sibutramine and the management of obesity. Expert Opin Pharmacother. 2004 Mar;5(3):633-42. To Reference
Ref 28Curr Top Med Chem. 2006;6(17):1801-23.Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. To Reference
Ref 29Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4. To Reference
Ref 30Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. To Reference
Ref 31Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. Clin Neuropharmacol. 2009 Jul-Aug;32(4):179-82. To Reference
Ref 32Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. To Reference
Ref 33Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543